Remoxy's Abuse Liability Study May Offer Clues On FDA's Upcoming Opioid Guidance
Executive Summary
FDA’s response to new data on Remoxy could serve as a model for how the agency expects to deal with the abuse-deterrent formulations it is encouraging for oxycodone and other opioids.
You may also be interested in...
Pfizer’s Remoxy Clears Manufacturing Hurdle, Still Needs BE, Abuse-Potential Studies
Extended-release oxycodone product has potential for broader abuse-deterrent claims than OxyContin; Pfizer expects to resubmit Remoxy to FDA by mid-2015.
Remoxy’s "Complete Response" Letter Has No Clear Culprit But Many Suspects
Legal and safety issues continue to swirl around Pfizer and Pain Therapeutics’ Remoxy as it deals with the product’s second “complete response” letter in less than three years.
Remoxy’s "Complete Response" Letter Has No Clear Culprit But Many Suspects
Legal and safety issues continue to swirl around Pfizer and Pain Therapeutics’ Remoxy as it deals with the product’s second “complete response” letter in less than three years.